Ionis Pharmaceuticals (IONS) Sets A Results Webcast, Is The Stock 51% Undervalued?

Why Ionis Pharmaceuticals Is Back In Focus

Ionis Pharmaceuticals (IONS) set a date for its next checkpoint. The company plans a live webcast on November 9 to review third quarter 2026 results and provide an update on progress across key RNA programs.

The webcast lands at a sensitive moment for Ionis Pharmaceuticals. The share price has fallen 25.1% over the past 90 days and is down 48.2% year to date, while the 5-year total shareholder return of 18.2% points to long-term gains despite recently fading momentum.

Compare this Ionis Pharmaceuticals reset with a curated set of RNA and healthcare peers by scanning the 33 healthcare AI stocks that could be lining up their own inflection points.

Ionis Pharmaceuticals now trades at a steep discount to both analyst targets and some intrinsic value estimates after a sharp slide. Is that gap a sign that caution is well placed, or has sentiment pushed the valuation too far?

Most Popular Narrative: 51% Undervalued

Ionis Pharmaceuticals last closed at $41.24 while the most followed narrative pegs fair value at $84.13, so the webcast drops into a story that already assumes a wide gap between price and projected worth.

Expanding TRYNGOLZA use in severe hypertriglyceridemia, supported by broad U.S. labeling, enthusiastic physician and payer feedback and a potential patient pool in the millions, can continue to lift revenue growth and improve operating leverage as Ionis Pharmaceuticals scales its commercial infrastructure.

See why 20 investors see Ionis Pharmaceuticals as 51% undervalued.

Result: Fair Value of $84.13 (UNDERVALUED)

Still, the Ionis Pharmaceuticals story can change quickly if further trial setbacks like eplontersen, or lost royalty streams such as pelacarsen, keep chipping away at confidence.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Next Steps

Sentiment around Ionis Pharmaceuticals is split, which is exactly when fresh eyes can matter most. Step in quickly and weigh the potential rewards for yourself with the 3 key rewards.

Hunting For More Ideas Beyond Ionis Pharmaceuticals?

Do not stop at Ionis Pharmaceuticals. Broaden your watchlist with fresh ideas from different angles so you are not relying on a single story to carry your returns.

• Target stability with businesses that pair healthy finances and low leverage using a list of solid balance sheet and fundamentals (24 results) that highlights balance sheets built to endure shocks.
• Pursue value by scanning 34 high quality undervalued stocks where strong fundamentals and discounted prices meet for investors willing to put in the work.
• Seek hidden upside by reviewing 19 high quality undiscovered gems before more attention crowds into the same opportunities you could have spotted early.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com